Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms 90Y-clivatuzumab tetraxetan, Clivatucyn, Clivatuzumab + [15] |
Target |
Mechanism MUC1 inhibitors(Mucin-1 inhibitors), MUC5AC inhibitors(Mucin-5AC inhibitors) |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | 90Y Clivatuzumab Tetraxetan | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic adenocarcinoma metastatic | Phase 3 | US | 01 Dec 2013 | |
Pancreatic adenocarcinoma metastatic | Phase 3 | AT | 01 Dec 2013 | |
Pancreatic adenocarcinoma metastatic | Phase 3 | BE | 01 Dec 2013 | |
Pancreatic adenocarcinoma metastatic | Phase 3 | CA | 01 Dec 2013 | |
Pancreatic adenocarcinoma metastatic | Phase 3 | FR | 01 Dec 2013 | |
Pancreatic adenocarcinoma metastatic | Phase 3 | IL | 01 Dec 2013 | |
Pancreatic adenocarcinoma metastatic | Phase 3 | PL | 01 Dec 2013 | |
Pancreatic adenocarcinoma metastatic | Phase 3 | ES | 01 Dec 2013 | |
Secondary malignant neoplasm of pancreas | Phase 3 | US | 01 Dec 2013 | |
Secondary malignant neoplasm of pancreas | Phase 3 | AT | 01 Dec 2013 |
Phase 3 | - | Gemcitabine+yttrium-90-labeled (90Y) clivatuzumab tetraxetan | cofyktahxp(lgibbvdaey) = the treatment arm of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine and best supportive care did not demonstrate a sufficient improvement in OS as compared to placebo plus low-dose gemcitabine and best supportive care. qxctnsexrq (abwlmayxvo ) | Negative | 14 Mar 2016 | ||
Gemcitabine+Placebo | |||||||
Phase 1/2 | Pancreatic Cancer First line | 100 | truynfqswi(hbeuqavchh) = zrwdyzzsgb kyrvndajid (hrwxsyusem ) | - | 01 Feb 2012 | ||
Phase 1/2 | 42 | ywksnmjdpf(utyugqbatt) = improved lqqoqttyow (jjkfmikmcc ) | - | 01 Feb 2011 | |||
Phase 1/2 | - | lkwghupabg(qbvwjdlldz) = flgvvlsgqq pqyqwyvhti (mdrewpslgb ) View more | - | 20 May 2010 |